CN102260250A - (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof - Google Patents
(-) doxazosin mesylate type IV crystal as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102260250A CN102260250A CN2011101851587A CN201110185158A CN102260250A CN 102260250 A CN102260250 A CN 102260250A CN 2011101851587 A CN2011101851587 A CN 2011101851587A CN 201110185158 A CN201110185158 A CN 201110185158A CN 102260250 A CN102260250 A CN 102260250A
- Authority
- CN
- China
- Prior art keywords
- doxazosin
- mesylate
- hydrochloride
- preparation
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention provides (-) doxazosin mesylate, polymorphous compounds thereof, a preparation containing the (-) doxazosin mesylate and applications of the (-) doxazosin mesylate, the compounds and the preparation in preparation of drugs for specifically treating benign prostatic hyperplasia.
Description
The application is that application number is CN 200610147193.9, and the applying date is on November 10th, 2006, and denomination of invention is divided an application for " (-) doxazosin mesylate, Preparation Method And The Use ".
Technical field
The preparation that the present invention relates to have optically active (-) doxazosin mesylate and contain this salt, it can have and acts on intraprostatic α specifically
1Acceptor can reduce the systemic reaction of Doxazosin simultaneously.More specifically, I type, II type, III type, IV type, V-type or VI type crystallization preparation and their purposes in the medicine of preparation specific treatment benign prostatic hyperplasia that the present invention relates to optically active (-) (left-handed) doxazosin mesylate and I type thereof, II type, III type, IV type, V-type or the crystallization of VI type and use this optically active (-) doxazosin mesylate.
Background technology
(benign prostatic hyperplasia BPH) is one of common, multiple male sex's senile disease to benign prostate hyperplasia.The at present operative treatments that adopt of BPH though effect is better, still have the symptom of 20% patient with operation not alleviated more at all; Therefore people make every effort to seek medicine and the alternative surgical intervention of damaging little non-operative treatment.
The urinary tract obstruction performance that BPH patient occurs comes from the mechanical obstruction that increases due to the prostate gland on the one hand, another more chief reason be that the dynamic property that prostate gland and bladder neck smooth muscle contraction cause is blocked.Discover, sympathetic nervous system to prostate gland level and smooth myofunctional adjusting bringing into play important effect; During as the whole nerve of spinal anesthesia retardance, can cause urethral occlusive drops 47%, blocking-up α is subjected to physical efficiency to produce similar hypotensive effect.These dynamic variation explanations, the sympathoadrenal of drug block domination prostate gland motion is plain can be neural, has the important clinical meaning, and this has constituted the basis of α receptor-blocking agent treatment BPH.
The α acceptor extensively distributes in vivo, in urogenital system, be distributed in the prostate gland, in the coating, urethra, neck of urinary bladder, especially prostate gland matrix at most.The α acceptor can be divided into α again
1And α
2Acceptor.Discover that being distributed on the prostate gland unstriated muscle mainly is α
1Acceptor.Therefore, to α
1/ α
2Acceptor has the antagonist of high selectivity, can improve urinary tract obstruction symptom (Eri LM, Tveter KJ effectively, α-Blockadein the treatment of symptomatic benign prostatic hyperplasia, J Urol., 1995,154:923～934.).
(±) Doxazosin (Doxazosin) is first disclosed as US4, and in 188,390, this medicine is by the exploitation of Pfizer company, and in listing in 1988, is long-acting selectivity α
1Receptor blocking agent, commercially available Doxazosin preparation is a mesylate at present, is to contain left-handed and the raceme mixture dextrorotation Doxazosin.
Although (±) Doxazosin is as selectivity α
1Receptor blocking agent, can alleviate the symptom of BPH urinary tract obstruction, but find that it has the side effect of very tangible cardiovascular aspect, (Lepor H such as ypotension, dizzy, headache, dry, uneasiness, anxiety, perspiration, tachycardia and flush for example, Knapp-Maloney G, Sunshine H.A dose titration study evaluating terazosin, aselective, once-a-day α
1-blocker for the treatment of symptomatic benignprostatic hyperplasia, J Urol., 1990a, 144 (6): 1393～7.).
Hatano etc. have studied (±) Doxazosin and enantiomorph (+) Doxazosin and (-) Doxazosin thereof pharmacological characteristics (Hatano A at human prostate tissue by putting aglucon and isolated experiment, Tang R, Walden PD, et al.The α-adrenoceptor antagonist properties of the enantiomers ofdoxazosin in the human prostate, Eur J Pharmacology, 1996,313 (1-2): 135～143.).Result of study shows that (±) Doxazosin and enantiomorph thereof are to α
1Acceptor has highly selective and high-affinity.Isolated experiment proves that (±) Doxazosin and enantiomorph competitive antagonism phyenlephrinium thereof cause the stripped prostate gland smooth muscle contraction reaction of people, and three's parameter for antagonist is pA
2Be worth identical (YamadaS, Suzuki M, Tanaka C, et al.Comparative study on α
1-adrenoceptorantagonist binding in human prostate and aorta, Clin.Exp.Pharmacol Physiol., 1994,21 (5): 405～11).Therefore, (±) Doxazosin, (+) Doxazosin and (-) Doxazosin become the major issue that people extremely are concerned about to the stereoselectivity of cardiovascular systems.If the some medicines in two enantiomorphs are weaker than another enantiomorph to the effect of cardiovascular systems and also are weaker than (±) Doxazosin simultaneously, then this medicine may become the little and more single-minded single enantiomer medicine of treatment BPH effect of cardiovascular systems side effect.
Denomination of invention is the effect that discloses the selective therapy benign prostate hyperplasia of (+) Doxazosin in the WO94/09785 communique of " composition of treatment benign prostatic hyperplasia and atherosclerotic method and (+) Doxazosin " (Methods and Compositions of (+) Doxazosin for the Treatmentof Benign Prostatic Hyperplasia and Atherosclerosis), wherein be described to: " (-) Doxazosin is brought out hypotension, and (+) Doxazosin does not have hypotension; Therefore (+) Doxazosin is better than (±) Doxazosin, is more suitable in the treatment benign prostate hyperplasia.Clinical human dosage is 0.5～10mg every day, single or part vic; Dose,optimum 0.5～5mg every day, single or part vic ".But in the denomination of invention that same applicant submits to is the effect that also discloses the selective therapy benign prostate hyperplasia of (-) Doxazosin in " composition of treatment benign prostatic hyperplasia and atherosclerotic method and (-) Doxazosin " (Methods andCompositions of (-) Doxazosin for the Treatment of Benign Prostatic Hyperplasiaand Atherosclerosis) WO94/09783 communique, wherein be described to: " (+) Doxazosin is brought out hypotension, and (-) Doxazosin does not have hypotension; Therefore (-) Doxazosin is better than (±) Doxazosin, is more suitable in the treatment benign prostate hyperplasia.Clinical human dosage is 0.5～10mg every day, single or part vic; Dose,optimum 0.5～5mg every day, single or part vic ".
Therefore, can think that the effect about the selective therapy BPH of (-) or (+) Doxazosin remains unclear.In addition, about the specificity of (-) or (+) Doxazosin treatment BPH, the prior art file is also unclear even contradictory.Therefore, the new drug for development treatment BPH causes confusion.
Simultaneously, do not have to disclose content in the above-mentioned document yet, therefore, know little about it at present yet for the salt of optical activity Doxazosin about the salt of optical activity Doxazosin.
The present inventor etc. have found hydrochloride and polymorphic form-I type, II type and the crystallization of III type of (-) Doxazosin by long-term further investigation.In addition, the inventor etc. also find can obtain the effect of good curing BPH by adopting (-) Doxazosin hydrochloride, can reduce dosage simultaneously, and reduce the generation of cardiovascular aspect side reaction.(-) Doxazosin hydrochloride, and polymorphic form-I type, II type and the crystallization of III type have applied for that on September 8th, 2004 denomination of invention is the patent of invention of optically active doxazosin, application number: 200410076821.X.
Summary of the invention
The present inventor etc. have finished the present invention on the basis that (-) Doxazosin hydrochloride is further studied.
The invention discloses:
1. (-) doxazosin mesylate.
2. as the mesylate of 1 described (-) Doxazosin, for being the I type crystallization of locating to have diffraction peak about 11.01 °, 25.9 ° and 26.6 ° at 2 θ angles.
3. as the mesylate of 2 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 2.
4. as the mesylate of 2 described (-) Doxazosin, its DSC peak value is 251.95 ℃, 235.66 ℃ of starting points, heat enthalpy value/Jg
-1170.21.
5. as the mesylate of 2 described (-) Doxazosin, its DSC collection of illustrative plates as shown in figure 13.
6. as the mesylate of 1 described (-) Doxazosin, for being the II type crystallization that has diffraction peak about 15.20 °, 15.82 °, 22.10 ° and 22.79 ° at 2 θ angles.
7. as the mesylate of 6 described (-) Doxazosin, about 15.82 ° of the peak positions of its diffraction peak relative intensity maximum in 2 θ angles.
8. as the mesylate of 6 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 4.
9. as the mesylate of 6 described (-) Doxazosin, its DSC peak value is 255.62 ℃, 254.03 ℃ of starting points, heat enthalpy value/Jg
-1106.60.
10. as the mesylate of 6 described (-) Doxazosin, its DSC collection of illustrative plates as shown in figure 14.
11. as the mesylate of 1 described (-) Doxazosin, for being the III type crystallization of locating to have diffraction peak about 10.35 °, 20.45 ° and 22.68 ° at 2 θ angles.
12. as the mesylate of 11 described (-) Doxazosin, the peak position of diffraction peak relative intensity maximum is in about 22.68 degree of 2 θ angles.
13. as the mesylate of 11 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 6.
14. as the mesylate of 11 described (-) Doxazosin, its DSC peak value is 283.30 ℃, 276.74, and heat enthalpy value/Jg
-1143.54.
15. as the mesylate of 11 described (-) Doxazosin, its DSC collection of illustrative plates as shown in figure 15.
16. as the mesylate of 1 described (-) Doxazosin, for being the IV type crystallization of locating to have diffraction peak about 15.2 °, 22.67 ° and 24.75 ° at 2 θ angles.
17. as the mesylate of 16 described (-) Doxazosin, the peak position of diffraction peak relative intensity maximum is in about 24.75 degree of 2 θ angles.
18. as the mesylate of 16 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 8.
19. as the mesylate of 16 described (-) Doxazosin, the DSC data are 138.90 ℃ of peak values, 124.37 ℃ of starting points, heat enthalpy value/Jg
-134.07; Peak value 177.10,167.44 ℃ of starting points, heat enthalpy value/Jg
-112.30; Peak value 243.80,231.75 ℃ of starting points, heat enthalpy value/Jg
-144.06; Peak value 269.30, starting point 263.45, heat enthalpy value/Jg
-1One of 28.94.
20. as the mesylate of 16 described (-) Doxazosin, its DSC collection of illustrative plates as shown in figure 16.
21. as the mesylate of 1 described (-) Doxazosin, for being the V-type crystallization of locating to have diffraction peak about 15.83 °, 20.58 ° and 22.8 ° at 2 θ angles.
22. as the mesylate of 21 described (-) Doxazosin, the peak position of diffraction peak relative intensity maximum is in about 22.8 degree of 2 θ angles.
23. as the mesylate of 21 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 10.
24. as the mesylate of 21 described (-) Doxazosin, its DSC peak value is 247.91 ℃, 240.66, and heat enthalpy value/Jg
-1131.74.
25. as the mesylate of 21 described (-) Doxazosin, its DSC collection of illustrative plates such as Figure 17.
26. the mesylate of (-) as claimed in claim 1 Doxazosin is for being the VI type crystallization of locating to have diffraction peak about 15.89 °, 20.63 ° and 22.85 ° at 2 θ angles.
27. as the mesylate of 26 described (-) Doxazosin, the peak position of diffraction peak relative intensity maximum is in about 22.85 degree of 2 θ angles.
28. as the mesylate of 26 described (-) Doxazosin, for having the crystallization of X-ray diffraction pattern shown in Figure 12.
29. as the mesylate of 26 described (-) Doxazosin, its DSC peak value is 247.55 ℃, 240.82, and heat enthalpy value/Jg
-166.45.
30. as the mesylate of 26 described (-) Doxazosin, its DSC collection of illustrative plates as shown in figure 18.
31. a Doxazosin preparation contains arbitrary described (-) doxazosin mesylate of 1-29 and pharmaceutical carrier, and does not contain (+) Doxazosin in fact.
32. the purposes of the preparation of above-mentioned 1-29 described (-) doxazosin mesylate and above-mentioned 30 in the medicine of preparation specific treatment benign prostatic hyperplasia.
Description of drawings
Fig. 1 is preparation example 3 gained (-) doxazosin mesylate I type crystalline infrared absorption spectruies.
Fig. 2 is preparation example 3 gained (-) doxazosin mesylate I type crystalline X-ray diffraction spectrum.
Fig. 3 is preparation example 2 gained (-) doxazosin mesylate II type crystalline infrared absorption spectruies.
Fig. 4 is preparation example 2 gained (-) doxazosin mesylate II type crystalline X-ray diffraction spectrum.
Fig. 5 is preparation example 4 gained (-) doxazosin mesylate III type crystalline infrared absorption spectruies.
Fig. 6 is preparation example 4 gained (-) doxazosin mesylate III type crystalline X-ray diffraction spectrum.
Fig. 7 is preparation example 7 gained (-) doxazosin mesylate IV type crystalline infrared absorption spectruies.
Fig. 8 is preparation example 7 gained (-) doxazosin mesylate IV type crystalline X-ray diffraction spectrum.
Fig. 9 is preparation example 5 gained (-) doxazosin mesylate V-type crystalline infrared absorption spectruies.
Figure 10 is preparation example 5 gained (-) doxazosin mesylate V-type crystalline X-ray diffraction spectrum.
Figure 11 is preparation example 6 gained (-) doxazosin mesylate VI type crystalline infrared absorption spectruies.
Figure 12 is preparation example 6 gained (-) doxazosin mesylate VI type crystalline X-ray diffraction spectrum.
Figure 13 is preparation example 3 gained (-) doxazosin mesylate I type crystalline dsc analysis collection of illustrative plates.
Figure 14 is preparation example 2 gained (-) doxazosin mesylate II type crystalline dsc analysis collection of illustrative plates.
Figure 15 is preparation example 4 gained (-) doxazosin mesylate III type crystalline dsc analysis collection of illustrative plates.
Figure 16 is preparation example 7 gained (-) doxazosin mesylate IV type crystalline dsc analysis collection of illustrative plates.
Figure 17 is preparation example 5 gained (-) doxazosin mesylate V-type crystalline dsc analysis collection of illustrative plates.
Figure 18 is preparation example 6 gained (-) doxazosin mesylate VI type crystalline dsc analysis collection of illustrative plates.
Embodiment
Below specifically introduce the present invention, the present invention says and refers to that (-) of the present invention doxazosin mesylate is meant that systematic naming method is (-) 4-amino-2-[4-(1,4-benzo dioxolane-2-carbonyl) piperazine-1-yl]-6, single mesylate of the compound of 7-dimethoxyquinazoline has as shown in the formula the structure shown in (II):
(-) of the present invention doxazosin mesylate should be optically pure basically material, so-called optical purity is meant in (-) doxazosin mesylate, according to preparation technology, in fact not containing or contain content does not influence (-) Doxazosin of (+) Doxazosin of pharmacologically active of (-) Doxazosin and the mixture of (+) Doxazosin.So-called content does not influence the mixture of the pharmacologically active of (-) Doxazosin, and the ee value should be more than 80%, and is preferred more than 90%, more preferably more than 95%, preferred again more than 98%, most preferably more than 99% or 100%.
(-) doxazosin mesylate has multiple crystal formation, has had now found that I type, II type, III type, IV type, V-type or the crystallization of VI type of following (-) doxazosin mesylate.
Six kinds of crystalline physico-chemical properties are as follows:
1. crystal formation I (unformed):
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: do not have the fixed fusing point
Infrared spectra: see Fig. 1
X-ray powder diffraction: see Fig. 2
Dsc analysis collection of illustrative plates: see Figure 13
2. crystal form II:
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: 250.4～268.9
Infrared spectra: see Fig. 3
X-ray powder diffraction: see Fig. 4
Dsc analysis collection of illustrative plates: see Figure 14
3. crystal form II I:
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: 268.2～270.3
Infrared spectra: see Fig. 5
X-ray powder diffraction: see Fig. 6
Dsc analysis collection of illustrative plates: see Figure 15
4. form IV:
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: 238.4～249.6
Infrared spectra: see Fig. 7
X-ray powder diffraction: see Fig. 8
Dsc analysis collection of illustrative plates: see Figure 16
5. crystal form V:
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: 246.8～248.2
Infrared spectra: see Fig. 9
X-ray powder diffraction: see Figure 10
Dsc analysis collection of illustrative plates: see Figure 17
6. crystal form V I:
Solubleness: be dissolved in water, methyl alcohol, ethanol, dimethyl sulfoxide (DMSO) isopolarity solvent; Be insoluble to weak polar solvent and non-polar solvents such as sherwood oil, benzene such as acetone, chloroform, methylene dichloride.
Fusing point: 268.4～269.2
Infrared spectra: see Figure 11
X-ray powder diffraction: see Figure 12
Dsc analysis collection of illustrative plates: see Figure 18
Specifically, the crystallization of I type, its at 2 θ angles 11.0 °, 25.9 ° and 26.6 ° etc. located diffraction peak, the diffraction peak base peak is positioned at about 25.9 °.The infrared maximum absorption of this I type crystalline (-) doxazosin mesylate is positioned at wave number 1600cm
-1About locate, in addition at 1500cm
-1About and 1650cm
-1About absorption peak also stronger.
Concrete, I type crystalline diffracting spectrum is summarized as follows among Fig. 2:
I type crystalline DSC collection of illustrative plates is summarized as follows among Figure 13:
| Crystal formation | Peak value (peak)/℃ | Starting point (onset)/℃ | Heat enthalpy value/Jg-1 |
| I | 251.95 | 235.66 | 170.21 |
Observe from above-mentioned collection of illustrative plates, in fact the I type crystallization of (-) doxazosin mesylate belongs to amorphous substance.
The mesylate II type crystallization of (-) Doxazosin, its at 2 θ angles about 15.2 °, 15.82 ° and 22.7 ° located diffraction peak, its diffraction peak base peak is positioned at about 15.82 °.The infrared maximum absorption of this II type crystalline (-) doxazosin mesylate also is to be positioned at wave number 1600cm
-1About, simultaneously at wave number 1100～1200cm
-1, 1200～1300cm
-1With 1400～1500cm
-1Between all have extremely strong absorption.
Concrete, II type crystalline diffracting spectrum is summarized as follows among Fig. 4:
II type crystalline DSC collection of illustrative plates is summarized as follows among Figure 14:
| Crystal formation | Peak value (peak)/℃ | Starting point (onset)/℃ | Heat enthalpy value/Jg-1 |
| II | 255.62 | 254.03 | 106.60 |
The III type crystallization of the mesylate of (-) Doxazosin, its at 2 θ angles about 10.35 °, 20.45 ° and 22.68 ° located diffraction peak, its diffraction peak base peak is positioned at about 22.68 °.The infrared maximum absorption of this II type crystalline (-) doxazosin mesylate also is to be positioned at wave number 1600cm
-1About, simultaneously at wave number 1200-1300cm
-1About and 1400-1500cm
-1About also have stronger absorption.
Concrete, III type crystalline diffracting spectrum is summarized as follows among Fig. 6:
III type crystalline DSC collection of illustrative plates is summarized as follows among Figure 15:
| Crystal formation | Peak value (peak)/℃ | Starting point (onset)/℃ | Heat enthalpy value/Jg-1 |
| III | 283.30 | 276.74 | 143.54 |
The mesylate IV type crystallization of (-) Doxazosin, its at 2 θ angles about 15.2 °, 22.67 ° and 24.75 ° located diffraction peak, its diffraction peak base peak is positioned at about 24.75 °.The infrared maximum absorption of this IV type crystalline (-) doxazosin mesylate also is to be positioned at wave number 1600cm
-1About, simultaneously at wave number 1400～1500cm
-1With 1600～1700cm
-1Between all have extremely strong absorption.
Concrete, IV type crystalline diffracting spectrum is summarized as follows among Fig. 8:
IV type crystalline DSC collection of illustrative plates is summarized as follows among Figure 16:
The mesylate V-type crystallization of (-) Doxazosin, its at 2 θ angles about 15.83 °, 20.58 ° and 22.8 ° located diffraction peak, its diffraction peak base peak is positioned at about 22.8 °.The infrared maximum absorption of this V-type crystalline (-) doxazosin mesylate also is to be positioned at wave number 1600cm
-1About, simultaneously at wave number 1200～1300cm
-1With 1400～1500cm
-1Between all have extremely strong absorption.
Concrete, V-type crystalline diffracting spectrum is summarized as follows among Figure 10:
V-type crystalline DSC collection of illustrative plates is summarized as follows among Figure 17:
| Crystal formation | Peak value (peak)/℃ | Starting point (onset)/℃ | Heat enthalpy value/Jg-1 |
| V | 247.91 | 240.66 | 131.74 |
The mesylate VI type crystallization of (-) Doxazosin, its at 2 θ angles about 15.89 °, 20.63 ° and 22.85 ° located diffraction peak, its diffraction peak base peak is positioned at about 22.85 °.The infrared maximum absorption of this VI type crystalline (-) doxazosin mesylate also is to be positioned at wave number 1600cm
-1About, simultaneously at wave number 1200～1300cm
-1, 1400～1500cm
-1With 1600～1700cm
-1Between all have extremely strong absorption.
Concrete, VI type crystalline diffracting spectrum is summarized as follows among Figure 12:
VI type crystalline DSC collection of illustrative plates is summarized as follows among Figure 18:
| Crystal formation | Peak value (peak)/℃ | Starting point (onset)/℃ | Heat enthalpy value/Jg-1 |
| VI | 247.55 | 240.82 | 66.45 |
Below the preparation method of (-) of the present invention doxazosin mesylate is introduced.
(-) of the present invention doxazosin mesylate can adopt conventional method for optical resolution to carry out.For example, can be undertaken by splitting commercially available racemize Doxazosin (following note is made (±) Doxazosin), at first, split by chromatography or crystallization process then and obtain (-) Doxazosin free alkali, promptly afterwards with the methylsulfonic acid acidifying with commercially available (±) Doxazosin salinization.
For example, can use common preparation amount chromatographic column, adopt ordinary method to split according to common separation method, for example in moving phase, add chiral additives, by the interaction of chiral additives with the isolating racemize Doxazosin of wanting, make that (-) Doxazosin has different retention time with (+) Doxazosin, thereby realize separating.Afterwards, remove chiral additives,, can obtain (-) of the present invention doxazosin mesylate with methylsulfonic acid (perhaps the organic solvent solution of methylsulfonic acid etc.) acidifying.
Perhaps, also can adopt chiral separation post, carry out chromatographic separation according to ordinary method with chirality padding.
In addition, not by (±) Doxazosin is split, but, synthesize afterwards by chiral intermediate is split, also can directly obtain optically active left-handed Doxazosin or doxazosin mesylate, i.e. (-) Doxazosin or (-) doxazosin mesylate.
For example, can be at first the racemize benzodioxane base carbonyl piperazine (hereinafter to be referred as side chain alkali I) of formula (III) be split,
Obtain the left-handed benzodioxane base carbonyl piperazine shown in the formula (IV) (hereinafter to be referred as (-) side chain alkali I),
Then with the dimethoxyquinazoline shown in the formula V (wherein X represents leavings group such as halogen (chlorine, bromine, iodine etc.), lower alkoxy or lower alkylthio etc.) condensation,
Obtain (-) Doxazosin free alkali or the salt shown in the formula (VI),
For example solution such as methylsulfonic acid-methyl alcohol or methylsulfonic acid-ethanol acidifying of free alkali with formula (VI) can obtain (-) the of the present invention doxazosin mesylate shown in the formula (II).
When splitting side chain alkali I, can adopt conventional method for splitting, generate diastereomeric salt as adopting with the optical activity acid-respons, according to the dissolubility difference of the salt that generates, realize the fractionation of racemization side chain alkali I.As optically active acid of being adopted, D-tartrate, D-diacetyl tartaric acid, D-dibenzoyl tartaric acid, D-camphorsulfonic acid, L-L-glutamic acid etc. are for example arranged.Consider preferred D-tartrate from aspects such as being easy to get of raw material, prices.
In addition, except splitting side chain alkali I, also at first racemic acid (hereinafter to be referred as side-chain acid II) or its reactive derivatives (as etheride, acid anhydrides, ester etc.) of split-type (VII) expression,
Obtain (-) side-chain acid II of formula (VIII) expression or change its reactive derivatives (as etheride, ester etc.) into,
Then with the intermediate III reaction of the formula (IX) of other preparation expression,
Obtain (-) Doxazosin free alkali or the salt shown in the formula (VI),
For example solution such as methylsulfonic acid-methyl alcohol or methylsulfonic acid-ethanol acidifying of free alkali with formula (VI) can obtain (-) the of the present invention doxazosin mesylate shown in the formula (II).
The reactive derivatives of above-mentioned side-chain acid II, the compound acid anhydrides such as lower alkyl acid anhydrides, the carbonic acid monoesters acid anhydride etc. that form of side-chain acid and other acid for example, etherides such as the ester that becomes with N-succinimide, phthalic imidine etc., acyl chlorides, acylbromide.
The method for splitting of side-chain acid II can adopt ordinary method, for example with optically active alkali reaction, forms diastereomeric salt, according to the dissolubility difference of the salt that generates, realizes the fractionation of racemization side-chain acid II.As adoptable optically active alkali, for example Chang Yong optical activity alkaloid such as brucine, vauqueline, quinoline are peaceful, Quinidine, trimethyl-xanthine, ephedrine, D or L-α-Ben Yian, D or L-propyloxy phenyl amine etc.
Application number in the applicant's application is: in the experimental example of the invention of 200410076821.X, obtained at α
1In specific inhibition agent (±) doxazosin mesylate of acceptor, (+) Doxazosin hydrochloride and (-) Doxazosin hydrochloride, the doxazosin mesylate enantiomorph is to cardiovascular systems α
1The blocking effect of acceptor has stereoselectivity, and wherein the effect of (-) Doxazosin hydrochloride is the most weak.That is to say that the hypotensive effect of (-) Doxazosin hydrochloride (comprising systolic pressure and diastolic pressure) significantly is lower than (±) doxazosin mesylate and (+) Doxazosin hydrochloride.On the other hand, reduce the activity that bladder is urinated and pressed from (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate, three's maximum reducing amplitude is respectively 6.80 ± 3.21,7.64 ± 3.14 and 7.52 ± 2.86 mmH
2O (means standard deviation), three's maximum retarding effect no significant difference (P＞0.05).In addition, (+) Doxazosin hydrochloride, (±) doxazosin mesylate and (-) Doxazosin hydrochloride do not have obvious influence (P＞0.05) to pressure value in the bladder basis, and the Doxazosin enantiomorph does not have stereoselectivity to the effect of normal anesthetized rat urinary bladder reflex.So, when purpose is for the benign prostatic hyperplasia of treatment treatment specifically, the preferred conclusion of using (-) Doxazosin hydrochloride.
And the present invention is by further experimentation on animals, (-) Doxazosin hydrochloride and the bioavailability of (-) doxazosin mesylate are studied, and the bioavailability that has obtained (-) doxazosin mesylate is better than the conclusion of (-) Doxazosin hydrochloride.
In addition, the invention still further relates to the doxazosin mesylate preparation of specific treatment benign prostatic hyperplasia, wherein contain (-) doxazosin mesylate, and do not contain (+) Doxazosin in fact.
Contain (-) doxazosin mesylate as defined above in the Doxazosin preparation of specific treatment benign prostatic hyperplasia of the present invention, wherein not contain (+) Doxazosin in fact also identical with the narration of front.
When being used for the specific treatment benign prostatic hyperplasia, the symptom of the usage of (-) of the present invention doxazosin mesylate, consumption etc. and disease, patient's age, race etc. are relevant.
For administering mode, can adopt oral or the parenteral administering mode, preferably adopt oral preparations.Certainly, also can adopt patch, suppository and various DDS (drug delivery system) drug-delivery preparation,, realize slowly-releasing or reduce first pass effect etc. to improve the release homogeneity of medicine.
For oral preparations, can adopt formulations such as tablet, capsule, dragee, granule, suspensoid or emulsion.
The said medicine preparation should contain the necessary pharmaceutical excipient of various preparations, adopts ordinary method or is prepared with concrete formulation corresponding preparation method.Because various excipient substances and formulation method belong to the general knowledge of this area, do not intend this is made qualification among the present invention.
For example, for preparation tablet or capsule, its preparation technology comprises (-) of the present invention doxazosin mesylate is mixed mutually with vehicle, makes softwood, granulation, encapsulated then or mix with lubricant etc. and to beat sheet and obtain corresponding capsule or tablet.In addition, according to circumstances, also can be with the mixture of (-) doxazosin mesylate and vehicle without the granulation direct compression.
At this, vehicle comprises used composition in the tablet of various routines or the capsule, weighting agent, disintegrating agent, tackiness agent etc.
At this, weighting agents commonly used such as weighting agent such as starch, lactose, Microcrystalline Cellulose, dextrin, N.F,USP MANNITOL, magnesium oxide, calcium sulfate.Disintegrating agents commonly used such as disintegrating agent such as carboxymethyl cellulose (and salt such as sodium salt), cross-linked carboxymethyl cellulose (and salt such as sodium salt), polyvinylpolypyrrolidone, sodium starch glycolate, low-substituted hydroxypropyl cellulose.Typical binders such as tackiness agent such as polyvidone (PVP), Vltra tears (HPMC), starch slurry.Lubricant such as Magnesium Stearate, calcium stearate etc.
In addition, also can be as the case may be, use can be given the auxiliary material of tablet or the specific release characteristics of capsule.
Because the consumption of (-) doxazosin mesylate is less in the preparation of the present invention, therefore, for uniformity coefficient of guaranteeing medicine etc., with mixed with excipients system softwood before, also can in advance (-) doxazosin mesylate be diluted with making tablet or capsular vehicle or other pharmaceutical excipients, make the back of doubly loosing and use.
Below enumerate preparation example, experimental example and embodiment the present invention is further specified, but be not that the present invention is constituted any restriction.
Unless stated otherwise, all per-cents all are weight percentage among the present invention
The preparation of preparation example 1 (-) Doxazosin alkali
(1) preparation of racemization N-(1,4-benzodioxane-2-carbonyl) piperazine
14.22g (50mmol) N-(1,4-benzodioxane-2-carbonyl) piperazine hydrochloride, 4g (100mmol) NaOH is dissolved in the 40ml water, uses 40ml dichloromethane extraction 3 times, gets 8.84g solid DL side chain alkali I behind the evaporate to dryness.Molar yield 71%.
(2) fractionation of racemization N-(1,4-benzodioxane-2-carbonyl) piperazine
12.4g (50mmol) (N-(1 for racemization side chain alkali I, 4-benzodioxane-2-carbonyl) piperazine) is dissolved in the 80ml methyl alcohol, join and be dissolved with in the tartaric 30ml aqueous solution of 7.5g D-, add small amount of seeds stirred crystallization 24hr under the room temperature, filter the tartrate of about 4.52g (-) side chain alkali.[α]=-24～-27 ° (c=1, H
2O), molar yield 46%.
(3) purifying (-) side chain alkali I (N-(1,4-benzodioxane-2-carbonyl) piperazine)):
4.0g the tartrate of (-)-side chain alkali adds 16ml 95% ethanol 4ml water recrystallization, obtains product 3.2g[α]=-30.5 (c=1, H
2O).
Secondarily purified the same.[α]＝-32.0(c＝1，H
2O)
(4) preparation (-) side chain alkali I (N-(1,4-benzodioxane-2-carbonyl) piperazine)):
5g adds 30ml water through the tartrate of secondarily purified (-) side chain alkali, and NaOH 0.6g after the dissolving, uses the 30mlX3 dichloromethane extraction, and drying gets 1.0g solid (-) side chain alkali purity and is about 96% behind the evaporate to dryness.
(5) preparation of (-) Doxazosin:
1.27 gram 2-chloro-4-amino-6,7 in the 30ml propyl carbinol ,-dimethoxyquinazoline, 1.4 gram (-) side chain alkali I, reflux 4 hours, cooled and filtered is washed with ethyl acetate then.50 ℃ of vacuum-dryings.Get 2.5 gram products.((-) Doxazosin hydrochloride crystal form II I)
(6) preparation of (-) Doxazosin alkali:
12.4 gram (-) Doxazosin hydrochloride joins 35ml DMF, in 18 ml waters, under 15-35 ℃ of condition, adding is dissolved with 3.6 gram K
2CO
3The 10 gram aqueous solution, settled solution. add 150 ml waters dilutions then. separate out solid, filter (-) Doxazosin alkali.
Synthesizing of preparation example 2 II type (-) doxazosin mesylates:
Above-mentioned synthetic (-) Doxazosin alkali joins adding 2.5 gram methylsulfonic acids in 50 milliliters of 25 ℃ of methyl alcohol, and the dissolving back is at 5 hours after-filtration of stirring at room, and 50 ℃ of vacuum-dryings get product 12.6 grams, and its crystallinity is the II type.
The preparation of preparation example 3 I type (-) doxazosin mesylates
0.2 being II type (-) doxazosin mesylate, the gram crystallinity adds in the 5ml water, after the reflux dissolving, and rapid crystallisation by cooling.Filter back 50 ℃ of vacuum-dryings.Get 0.12 gram I type (-) doxazosin mesylate.
The preparation of preparation example 4 III type (-) doxazosin mesylates
7.0 being I type (-) doxazosin mesylate, the gram crystallinity adds in the 28ml methyl alcohol, after the reflux dissolving, and reflux crystallization in 3 hours.Filter back 50 ℃ of vacuum-dryings.Get 0.9 gram III type (-) doxazosin mesylate.
The preparation of preparation example 5 V-type (-) doxazosin mesylates
Add in the 28ml methyl alcohol 7.0 the gram crystallinity is I type (-) doxazosin mesylate, after the reflux dissolving, be cooled to crystallizing at room temperature rapidly 10 hours.Filter back 50 ℃ of vacuum-dryings.Get 2.35 gram V-type (-) doxazosin mesylates.
The preparation of preparation example 6 VI (-) doxazosin mesylates
Add in the 20ml95% ethanol 4.0 the gram crystallinity is I type (-) doxazosin mesylate, after the reflux dissolving, be cooled to crystallizing at room temperature rapidly 10 hours.Filter back 50 ℃ of vacuum-dryings.Get 1.74 gram VI type (-) doxazosin mesylates.Add in the 10ml chloroform with 0.2 gram I type (-) doxazosin mesylate equally, after the reflux dissolving, filter insoluble part, be cooled to crystallizing at room temperature rapidly 10 hours.Filter back 50 ℃ of vacuum-dryings and also can obtain VI type (-) doxazosin mesylate.
The system of preparation example 7 IV (-) doxazosin mesylates
(-) Doxazosin alkali 6.2 grams join adding 2.5 gram methylsulfonic acids in 25 ml methanol, are heated to 55 ℃ of insulations 30 minutes. slowly be cooled to room temperature, and 5 hours after-filtration, 50 ℃ of vacuum-dryings get product 4.6 grams, and its crystallinity is the IV type.
The gained compound carries out the mensuration of X-ray powder diffraction, fusing point, infrared spectra respectively.
X-ray powder diffraction: German Bruker D8 ADVANCE type powder x-ray diffraction,
CuK α
1Radiation, graphite monochromator, 40KV, 120mA, 5-60 ° of 2 θ sweep limit, 2.4 °/minute of sweep velocitys, 0.02 ° of step-length;
Fusing point instrument: Switzerland BUCHI company, B-540 type fusing point instrument.
Infrared analysis instrument: Nicolet Magna-IR 550 type KBr sheets
Dsc
Instrument: Perkin-Elmer DSC7 type
Experiment condition: equilibrium temperature: 30 ℃, heat-up rate: 10 ℃/min, temperature range: 30-280 ℃
Experimental example 1 Doxazosin and enantiomorph thereof are to rabbit blood vessel α
1The antagonistic properties of acceptor
This experimental example has been studied α by models such as the stripped thoracic aorta of rabbit, arteria carotis communis
1Receptor antagonist (±) doxazosin mesylate and enantiomorph thereof (hydrochloride) are to cardiovascular α
1The antagonistic action of acceptor and the pharmacological characteristics on blood vessel thereof.
Experimental technique
White rabbit is planted by New Zealand, and is male, body weight 2.5～3.5Kg, and effluent north medical university Experimental Animal Center provides.
(±) doxazosin mesylate, commercially available product; (+) Doxazosin hydrochloride and (-) Doxazosin hydrochloride make according to preparation example 1 (5) method; Desipramine hydrochloride, propranolol hydrochloride, desoxycorticosterone acetate (DOCA), prazosin hydrochloride and noradrenaline bitartrate (NA) are available from Sigma company.Remove desoxycorticosterone acetate (DOCA) and be dissolved in 1, outside the 2-propylene glycol, other reagents are dissolved in the dual distilled water.
After the light anaesthesia of rabbit ear vein injection vetanarcol, the sacrificed by exsanguination animal.Take out thoracic aorta, arteria carotis communis, arteria auricularis, mesenteric artery and pulmonary artery immediately, peel off fat and other reticular tissue.For fear of the influence of blood vessel endothelium lax pair experimental result, remove endothelium with shaggy polyethylene intubate (external diameter the is slightly less than vessel diameter) intravascular space that carefully rubs.Parallelly in arterial ring sample (length the is 4mm) tube chamber penetrate two tungsten wire loops, one ring is fixed on the fixed support point of 10ml bath below, another tungsten wire loops is connected in the tension pick-up of bath top, transmitter is connected in four road physiographs (ERT-884 type, Kaifeng friend woods Electronics Co., Ltd.).
Impose the preload of 4.0g, 3.0g, 2.0g, 1.5g and 2.5g respectively in thoracic aorta, arteria carotis communis, arteria auricularis, mesenteric artery and pulmonary artery sample, and make sample balance 1.5h in nutritive medium.Nutrient composition (mmolL
-1) being: NaCl 133, and KCl 4.7, NaH
2PO
41.35, NaHCO
316.3, MgSO
40.61, glucose 7.8 and CaCl
22.52 pH 7.2.Nutritive medium insulation 37 ℃ ± 0.5 continues logical 95% O that contains
2+ 5% CO
2Gas mixture.Add norepinephrine (NA) preshrinking blood vessel before the experiment beginning, treat tension stability after, add vagusstoff (Ach) 1molL
-1To check having or not of endothelial function, the Ach of this concentration does not produce any stretching reaction as the index of removing endothelium fully.
In bath solution, add desipramine hydrochloride (10
-7MolL
-1), desoxycorticosterone acetate (DOCA) (5 * 10
-6MolL
-1) and propranolol hydrochloride (10
-6MolL
-1), block re-uptake and the beta receptor of NA respectively.Each sample is made NA accumulation amount effect curve 6 times, discards the 1st, 2 time experimental result, and is carrying out preceding 30 minutes of the 4th, 5,6 experiment, with three different concns (0.03,0.1 and 0.3molL
-1) (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride add bath solution respectively.Each sample is only given a kind of antagonist.Use the Schild Plot in the PHARM/PCS program (the 4th edition) to calculate pA
2Value.(sample number is seen each table)
1. (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride bring out the influence that the rabbit thoracic aorta shrinks to norepinephrine (NA)
Before giving various Doxazosin, each organizes the E of thoracic aorta NA amount effect curve
MaxAnd EC
50Value no significant difference (P＞0.05).Each group gives (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride 0.03,0.1,0.3molL respectively
-1After, along with antagonist concentration increases, the NA amount effect curve is parallel to move to right, but E
MaxConstant (P＞0.05).The slope of the Schild plot of (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride equals 1 (P＞0.05), shows that the mode of action of three kinds of antagonists inhibition NA contractile responses is a competitive antagonism.The pA of (+) Doxazosin
2Value is obviously greater than the pA of (±) Doxazosin
2Value, and the pA of (-) Doxazosin
2Value is significantly less than the pA of (±) Doxazosin
2Value the results are shown in Table 1.
2. (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride bring out the influence that the rabbit arteria carotis communis shrinks to norepinephrine (NA)
Before giving various Doxazosin, each organizes the E of thoracic aorta NA amount effect curve
MaxAnd EC
50Value no significant difference (P＞0.05).Give three different concns (0.03,0.1,0.3 μ molL respectively
-1) (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride after, along with antagonist concentration increases, the NA amount effect curve all presents parallel moving to right, E
MaxBe worth constant (P＞0.05).(the Schild plot slope of (±) doxazosin mesylate, (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride equals 1 (P＞0.05), shows that the mode of action of three kinds of antagonists inhibition NA contractile responses is a competitive antagonism.The pA of (+) Doxazosin
2Obviously greater than (±) Doxazosin, and the pA of (-) Doxazosin
2Value is significantly less than (±) Doxazosin, the results are shown in Table 1.
Table 1 Doxazosin and enantiomorph thereof are to stripped thoracic aorta of rabbit and carotid pA
2Value
Means standard deviation,
cCompare with (±) Doxazosin P＜0.01.
3. (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride bring out the influence of rabbit ear artery contractile response to norepinephrine (NA)
After giving Prazosin (Pra) hydrochloride 1,10,100nM, along with blocker concentration increases, the NA amount effect curve moves to right, and Schild plot analytical results shows, Pra act as noncompetitive antagonism (slope is less than 1).After giving (+) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (+) Doxazosin hydrochloride equals 1 (P＞0.05).After giving (-) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (-) Doxazosin hydrochloride equals 1 (P＞0.05).In addition, the pA of (-) Doxazosin hydrochloride
2Value is significantly less than the pA of (+) Doxazosin hydrochloride
2Value the results are shown in Table 2.
Table 2 Doxazosin enantiomorph is to the pA of the stripped arteria auricularis of rabbit
2Value
Means standard deviation,
*Compare with (+) Doxazosin P＜0.01,
▲ ▲P＜0.01 and 1 relatively.
4. (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride bring out the influence of rabbit mesenteric artery contractile response to norepinephrine (NA)
After giving Pra 1,10,100nM, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constant (P＞0.05), the slope of the Schild plot of Pra equals 1.After giving (+) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (+) Doxazosin hydrochloride equals 1.After giving (-) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (-) Doxazosin hydrochloride equals 1.In addition, the pA of (-) Doxazosin hydrochloride
2Value is significantly less than the pA of (+) Doxazosin hydrochloride
2Value the results are shown in Table 3.
Table 3 Doxazosin enantiomorph is to the pA of the stripped mesenteric artery of rabbit
2Value
Means standard deviation,
*Compare with (+) Doxazosin P＜0.01.
5. (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride bring out the influence of rabbit pulmonary artery contractile response to norepinephrine (NA)
After giving Pra 1,10,100nM, along with blocker concentration increases, the NA amount effect curve moves to right, and Schild plot analytical results shows that the effect of Pra belongs to noncompetitive antagonism (slope is less than 1).After giving (+) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (+) Doxazosin hydrochloride equals 1.After giving (-) Doxazosin hydrochloride 0.03,0.1,0.3 μ M, along with blocker concentration increases, the NA amount effect curve is parallel to move to right E
MaxBe worth constantly, the slope of the Schild plot of (-) Doxazosin hydrochloride equals 1.In addition, the pA of (-) Doxazosin hydrochloride
2Value is significantly less than the pA of (+) Doxazosin hydrochloride
2Value the results are shown in Table 4.
Table 4 Doxazosin enantiomorph is to the stripped Pulmonic pA of rabbit
2Value
Means standard deviation,
*Compare with (+) Doxazosin P＜0.01,
▲ ▲P＜0.01 and 1 relatively.
From result shown in above-mentioned table 1～4 as seen, at the stripped thoracic aorta of rabbit, arteria carotis communis rabbit ear artery, mesenteric artery and pulmonary artery, Doxazosin and three kinds of blocker antagonisms of enantiomorph NA thereof bring out the pA of contractile response
2Value is different, the pA of (-) Doxazosin hydrochloride
2Value is starkly lower than the pA of its raceme and (+) Doxazosin hydrochloride
2Value.Therefore, each enantiomorph is to rabbit arterial vascular smooth muscle α
1The blocking effect of acceptor has stereoselectivity, and wherein the effect of (-) Doxazosin hydrochloride is the most weak.
Experimental example 2 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat blood pressure and intraventricular pressure
Experimental technique
Male Wistar rat, body weight 250～300g, effluent north medical university Experimental Animal Center provides.
Reagent is with experimental example 1.
The mensuration of arteria carotis communis blood pressure: male Wistar rat, with 25% urethane (2g/kg, wherein 1g/kg subcutaneous injection, the 1g/kg abdominal injection) anesthesia, it is fixing to lie on the back, the stringer skin incision is done in the center, throat, the promoting the circulation of qi cannula separates manadesma, spatium intermusculare with tweezers, after the left carotid of dissociating to keep respiratory passage unblocked, fine rule ligation distal end, bulldog clamp is proximal part fixedly.On arterial wall, make a little otch with eye scissors, the hard polyethylene conduit (internal diameter 1mm) that will be filled with heparin (25kU/L) physiological saline inserts artery, the thin silk thread ligation is fixed, and the opposite side of pipe links to each other with eight road physiographs through threeway, pressure transducer, is used to measure the arteria carotis communis blood pressure.An electrocardioelectrode and a draw point are fastened with adhesive plaster, and it is subcutaneous that draw point thrusts the rat four limbs, and the guiding electrocardio is used to measure heart rate.No. 5 half infusion niidl links to each other with another threeway by sebific duct, wherein is filled with the physiological saline of emptying bubble.The stringer skin incision is done at left hind bone vein place, exposes femoral vein, and No. 5 half infusion niidls are thrust femoral vein, and immobilization with adhesive tape is used in order to intravenously administrable.
The mensuration of left ventricular pressure: male Wistar rat, with 25% urethane (2g/kg, wherein 1g/kg subcutaneous injection, 1g/kg abdominal injection) anesthesia, it is fixing to lie on the back, throat center stringer otch, trachea cannula, its distal end of ligation after the separation right carotid.Polyethylene catheter (internal diameter 1mm) is full of with heparin (25kU/L) physiological saline after threeway links to each other with eight road physiographs with pressure transducer.Bulldog clamp is clamped the arteria carotis communis proximal part, makes a little otch with eye scissors on arterial wall, with the above-mentioned polyethylene catheter of lubrication of liquid paraffin outer wall, and with the fine rule ligation on arteria carotis communis, both made incision not leak blood, allow conduit freely advance again.Open bulldog clamp afterwards, from indicating meter, can see the arteriotony waveform, treat that arteriotony is stable after, the polyethylene catheter in the arteria carotis communis is inserted left ventricle along aorta (in opening of aortic valve time); The moment blood pressure that conduit enters left ventricle descends suddenly, and pulse pressure difference obviously strengthens; Fixedly polyethylene catheter after waiting to stablize, is measured left ventricular pressure.Electrocardioelectrode links to each other with draw point, and draw point is thrust under the rat four limbs epidermis, and the guiding electrocardio is used to measure heart rate.No. 5 half infusion niidl links to each other with another threeway by sebific duct, wherein is filled with the physiological saline of emptying bubble.The stringer skin incision is done at left hind bone vein place, exposes femoral vein, and No. 5 half infusion niidls are thrust femoral vein, and immobilization with adhesive tape is equipped with intravenously administrable and uses.
1. (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate are to the influence of anesthetized rat arteria carotis communis pressure
(+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride dose-dependently ground reduce the arteria carotis communis systolic pressure, and the maximum reducing amplitude of (+) Doxazosin hydrochloride is obviously greater than (-) Doxazosin hydrochloride.(+) Doxazosin hydrochloride significantly is better than effect to systolic pressure to the reduction effect of arteria carotis communis diastolic pressure, and (-) Doxazosin hydrochloride does not have this phenomenon.(+) Doxazosin hydrochloride to the maximum reducing amplitude of diastolic pressure obviously greater than (-) Doxazosin hydrochloride.The intensity of step-down is (-) Doxazosin hydrochloride, (±) doxazosin mesylate and (+) Doxazosin hydrochloride by series arrangement from low to high successively.Decline percentage calculation ED with mean arterial pressure
30Value, the ED of (+) Doxazosin hydrochloride, (±) doxazosin mesylate and (-) Doxazosin hydrochloride
30Value is followed successively by 15.64 ± 9.40nmol/kg (means standard deviation), 45.93 ± 20.61nmol/kg and 128.81 ± 35.70nmol/kg, three kinds of medicine ED
30Ratio be 1: 2.94: 8.24, the antihypertensive effect of prompting (-) Doxazosin hydrochloride significantly is lower than (±) doxazosin mesylate and (+) Doxazosin hydrochloride.The results are shown in Table 5 and table 6.
Table 5 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat carotid artery systolic pressure
*P＜0.05,
*Compare with control group P＜0.01;
△P＜0.05,
△ △Compare with (+) Doxazosin P＜0.01; N=8.
Table 6 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat carotid artery diastolic pressure
*P＜0.05,
*Compare with control group P＜0.01;
△ △Compare with (+) Doxazosin P＜0.01; N=8.
2. (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate are to the influence of anesthetized rat left ventricular pressure
(+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and the equal dose-dependently of (±) doxazosin mesylate ground reduce left ventricular systolic pressure, the effect the strongest (table 7) during 250nmol/kg.With three kinds of medicines of dosage, the inhibition strength of its left ventricular systolic pressure from by force to weak be (+) Doxazosin hydrochloride, (±) doxazosin mesylate and (-) Doxazosin hydrochloride successively.Rat left ventricle transient pressure (± dp/dt) along with the increase of drug dose, the absolute value of ± dp/dt reduces gradually, and the effect during 250nmol/kg is the strongest.The intensity of three kinds of medicine inhibition ± dp/dt is (+) Doxazosin hydrochloride＞(±) doxazosin mesylate＞(-) Doxazosin hydrochloride.After (+) Doxazosin hydrochloride, (±) doxazosin mesylate and the administration of (-) Doxazosin hydrochloride femoral vein, except (+) Doxazosin hydrochloride 250nmol/kg significantly reduced heart rate (P＜0.01), other dosage and other two medicines were to the effect not statistically significant (P＞0.05) of rat heart rate.
Table 7 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat left ventricular pressure
*P＜0.05,
*Compare with control group P＜0.01;
△P＜0.05,
△ △Compare with (+) Doxazosin P＜0.01; N=8.
Conclusion: there are notable difference in (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate to the effect of anesthetized rat cardiovascular systems.Three kinds of medicines are (-) Doxazosin hydrochloride＜(±) doxazosin mesylate＜(+) Doxazosin hydrochlorides to hypotensive effect and the inhibiting intensity of heart of rat from low to high successively.Therefore, the Doxazosin enantiomorph is to anesthetized rat cardiovascular systems α
1The blocking effect of acceptor has stereoselectivity, and wherein the effect of (-) Doxazosin hydrochloride is the most weak.
Experimental example 3 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat intravesical pressure
Experimental technique
Male Wistar rat, body weight 250～300g, effluent north medical university Experimental Animal Center provides.
Reagent is with experimental example 1.
The sugar-free tyrode's solution is selected in the preparation of bladder perfusate for use, and its composition is (g/L): NaCl 8.0, and KCl 0.2, CaCl
20.2, MgCl
20.1, NaH
2PO
40.05, NaHCO
31.0.Perfusate is prepared with distilled water, and its most electrolyte ingredients at first are mixed with the higher mother liquor of concentration, faces with preceding each mother liquor is mixed in the desired amount, the redilution constant volume; CaCl
2And NaHCO
3Then before constant volume, add at last.
The mensuration male Wistar rat of intravesical pressure, the subcutaneous anesthesia of 25% urethane (1.2g/kg), it is fixing to lie on the back, cut skin and muscle along the lower abdomen median line, expose bladder, fixing a little with moistening cotton, overlapped the tweezers of silicone tube with the tip and gently carried bladder, at bladder top row Piercing.One self-control two-chamber polyethylene intubate is inserted intravesical, fix with the fine rule ligation, but not ligation ureter.The outer tube of this two-chamber polyethylene intubate links to each other with eight road physiographs with pressure transducer by threeway, is used to write down intravesical pressure; Inner tube links to each other with the constant speed pump, and the rate of flooding of bladder perfusate is 10ml/h.For the influence to intravesical pressure of the injection pressure that reduces inner tube, inner tube is than outer pipe range 2mm.Constant 30 ℃ of constant indoor temperature.No. 5 half infusion niidl links to each other with another threeway by sebific duct, wherein is filled with the physiological saline of emptying bubble.The stringer skin incision is done at left hind bone vein place, exposes femoral vein, and No. 5 half infusion niidls are thrust femoral vein, and immobilization with adhesive tape is equipped with intravenously administrable and uses.
After intravesical pressure is stablized 20 minutes, with syringe (1ml) the Doxazosin enantiomorph being injected in the rat body each parameter of intravesical pressure after the record administration from femoral venous catheter: presses, urinates at interval and the changing conditions of the capacity of urinating in the pressure of urinating, basis.Be worth in contrast with value before the medicine of each dosage.Experiment is divided into three groups at random: (1) (+) Doxazosin hydrochloride group, (+) Doxazosin hydrochloride is divided into three kinds of concentration, is followed successively by 5 * 10 from low to high
-6, 5 * 10
-5With 5 * 10
-4Mol/L is all by the administration of 0.05ml/100g body weight.Every rat gives a kind of medicine of concentration, 8 rats of each dosage group.(2) (-) Doxazosin hydrochloride group, (-) Doxazosin hydrochloride is divided into three kinds of concentration, is followed successively by 5 * 10 from low to high
-6, 5 * 10
-5With 5 * 10
-4Mol/L is all by the administration of 0.05ml/100g body weight.Every rat gives a kind of medicine of concentration, 8 rats of each dosage group.(3) (±) doxazosin mesylate group: (±) doxazosin mesylate is divided into three kinds of concentration, is followed successively by 5 * 10 from low to high
-6, 5 * 10
-5With 5 * 10
-4Mol/L is all by the administration of 0.05ml/100g body weight.Every rat gives a kind of medicine of concentration, 8 rats of each dosage group.By above dosage regimen, three kinds of concentration correspond respectively to medicine from low to high and at the intravital dosage of rat are: 2.5,25 and 250nmol/kg.
Experimental result
The equal dose-dependently of (+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate reduces the bladder pressure (table 8) of urinating, the maximum reducing amplitude of three kinds of medicines is respectively 6.80 ± 3.21,7.64 ± 3.14 and 7.52 ± 2.86 (means standard deviation), three's maximum retarding effect no significant difference (P＞0.05).In addition, (+) Doxazosin hydrochloride, (±) doxazosin mesylate and (-) Doxazosin hydrochloride do not have obvious influence (P＞0.05) to the intravesical pressure basic value.(+) Doxazosin hydrochloride, (-) Doxazosin hydrochloride and (±) doxazosin mesylate are to urinating at interval and voided volume all do not make significant difference (P＞0.05).
The influence that table 8 Doxazosin and enantiomorph thereof are urinated and pressed the anesthetized rat bladder
*P＜0.05,
*P＜0.01 is relatively preceding with administration; N=8.
Conclusion: (+) Doxazosin hydrochloride, (±) doxazosin mesylate and (-) Doxazosin hydrochloride are similar to the urinate action intensity of process of anesthetized rat bladder, there is not evident difference each other, therefore, the Doxazosin enantiomorph does not have stereoselectivity to the effect of normal anesthetized rat urinary bladder reflex.
The research of experimental example 4 (-) Doxazosin hydrochloride treatment benign prostatic hyperplasia optimal dose
Test method
Male Wistar rat, body weight 250～300g, effluent north medical university Experimental Animal Center provides.
Reagent is with experimental example 1.
1. the blood pressure determination of anesthetized rat arteria carotis communis is the same.
2. the anesthetized rat left ventricular pressure is measured the same.
3. the anesthetized rat cystomanometry is the same.
4. dosage setting (±) doxazosin mesylate, (+) Doxazosin hydrochloride and (-) Doxazosin hydrochloride all adopt gastric infusion.Every rat is only given a dosage, observes and write down the variation of artery mean pressure, left indoor pressure and intravesical pressure after the administration continuously, the maximum reaction of record, and calculate the percentage of maximum reaction.Experiment divides five dosage group: 0.05mg/kg, 0.08mg/kg, 0.2mg/kg, 0.3mg/kg and 0.4mg/kg, 5 rats of each dosage group.Dosage according to rat and people is converted (people's consumption mg/60kg=rat dosage mg/kg ÷ 5.4 * 60), and clinical people's consumption (oral dosage) of above-mentioned five dosage is respectively: 0.5mg/60kg, 0.8mg/kg, 2mg/60kg, 3mg/kg and 4mg/60kg.
Experimental result
1. medicine is to the influence of liquor-saturated rat carotid artery blood pressure
Table 9 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat carotid artery mean arterial pressure
*P＜0.05,
*P＜0.01 is relatively preceding with administration;
△P＜0.05,
△ △Compare with R (+) Doxazosin P＜0.01; N=5.
2. medicine is to the influence of anesthetized rat left ventricular pressure
Table 10 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat left ventricular pressure
*P＜0.05,
*P＜0.01 is relatively preceding with administration;
△P＜0.05,
△ △Compare with R (+) Doxazosin P＜0.01; N=5.
3. medicine is to the influence of anesthetized rat intravesical pressure
Table 11 Doxazosin and enantiomorph thereof are to the influence of anesthetized rat intravesical pressure
*P＜0.05,
*P＜0.01 is relatively preceding with administration; N=5.
Conclusion: can know by inference according to above-mentioned 3 result of experiment, clinical adult's every day is when oral (-) Doxazosin hydrochloride 0.8mg, 2mg, 3mg or 4mg, all can reduce the bladder pressure of urinating, and the effect of medicine strengthens with dosage.But, when reaching 4mg/ day above (give rat oral gavage (-) Doxazosin hydrochloride 0.4mg/kg, consumption 4mg/ day is equivalent to be grown up) as if dosage, the function of meeting remarkably influenced blood pressure and heart; Every day, oral (-) Doxazosin hydrochloride 4mg may make patient produce significantly cardiovascular systems untoward reaction.So the optimal clinical dosage range of adult's oral (-) Doxazosin hydrochloride every day treatment benign prostatic hyperplasia is 0.8mg～3mg.
The bioavailability of experimental example 5 (-) doxazosin mesylate and (-) Doxazosin hydrochloride relatively
With the cat is experimental animal, bioavailability to (-) doxazosin mesylate (preparation example 2 obtains) and (-) Doxazosin hydrochloride (preparation example 1 (5) obtains) is studied, adopt high performance liquid chromatography (HPLC) to detect, chromatographic column is octadecyl silane reverse-phase chromatographic column (4.6mm * 250mm, 5 μ m), moving phase is methyl alcohol-acetate buffer solution (Glacial acetic acid 15ml and 1ml triethylamine add water to 500ml) (55: 45), and flow velocity is 1mlmin
-1, fluorimetric detector, excitation wavelength lambda
Ex270nm, emission wavelength lambda
Em385nm.And utilize the 3p97 program, calculate Plasma Concentration-time data, relatively the bioavailability of (-) doxazosin mesylate and (-) Doxazosin hydrochloride.
1. methodological study result
Experiment showed, that blank plasma does not influence the mensuration of (-) Doxazosin and internal standard substance furazosin.(-) Doxazosin is respectively 98.6%, 99.5%, 100.3% in the rate of recovery of basic, normal, high three concentration; The RSD of standard deviation in a few days under three different concns of (-) Doxazosin is respectively 5.4% (lower concentration), 4.7% (middle concentration), 2.8% (high density).The RSD of standard deviation in the daytime under three different concns of (-) Doxazosin is respectively 6.3% (lower concentration), 5.9% (middle concentration), 3.9% (high density).(-) Doxazosin is at 40～500ngml
-1In the scope, concentration and peak area ratio are good linear relationship, and the minimum detection of this method is limited to 10ngml
-1, minimum quantitatively is limited to 40ngml
-1
2. bioavailability study
Animal is divided two groups at random, and the animal fasting is 24 hours before the experiment, respectively intramuscular injection ketaject injection (15mgkg
-1) and abdominal injection 25% urethane (1.0gkg
-1) anaesthetize.Anesthetized animal is faced upward the position fix, do trachea cannula, keep breathing unobstructed, and do duodenal intubation, in order to duodenal administration.Separate the right lateral thigh vein to be on the waiting list blood.Press same dose (2.0 μ molkg
-1) give (-) doxazosin mesylate and (-) Doxazosin hydrochloride respectively, respectively at before the administration and after the administration 10,30,60,90,120,180min gets blood 0.5ml through femoral vein, put the heparinization test tube, centrifugal (5000rmin-1,20min) separated plasma, blood plasma is put-20 ℃ of freezer storages, uses for surveying Plasma Concentration.
Test shows: in the anesthetized cat body, all reached the peak in 10 minutes behind (-) doxazosin mesylate and (-) Doxazosin hydrochloride duodenal administration, its peak concentration is respectively 1176.19 ± 1217.30ng/ml and 773.99 ± 715.12ng/ml.Two kinds of salt are learned to handle in the intravital Plasma Concentration of anesthetized cat by statistics has significant difference (p=0.0004).
Conclusion: the Plasma Concentration of (-) doxazosin mesylate is apparently higher than the Plasma Concentration of (-) Doxazosin hydrochloride.
Claims (7)
1. (-) doxazosin mesylate is for being the IV type crystallization of locating to have diffraction peak about 15.2 °, 22.67 ° and 24.75 ° at 2 θ angles.
2. (-) according to claim 1 doxazosin mesylate has following X-ray powder diffraction pattern:
3. (-) according to claim 1 doxazosin mesylate is for having the crystallization of X-ray diffraction pattern shown in Figure 8.
4. (-) according to claim 1 doxazosin mesylate, DSC data are 138.90 ℃ of peak values, 124.37 ℃ of starting points, heat enthalpy value/Jg
-134.07; Peak value 177.10,167.44 ℃ of starting points, heat enthalpy value/Jg
-112.30; Peak value 243.80,231.75 ℃ of starting points, heat enthalpy value/Jg
-144.06; Peak value 269.30, starting point 263.45, heat enthalpy value/Jg
-1One of 28.94.
5. the mesylate of (-) according to claim 1 Doxazosin, its DSC collection of illustrative plates as shown in figure 16.
6. a Doxazosin preparation contains arbitrary described (-) doxazosin mesylate of 1-5 and pharmaceutical carrier, and does not contain (+) Doxazosin in fact.
7. the purposes of the preparation of arbitrary described (-) doxazosin mesylate of claim 1-5 or claim 6 in the medicine of preparation specific treatment benign prostatic hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110185158 CN102260250B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510012968.7 | 2005-11-11 | ||
| CN200510012968 | 2005-11-11 | ||
| CN 201110185158 CN102260250B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610147193 Division CN100999519B (en) | 2005-11-11 | 2006-11-10 | (-) poly thaazoleazine methylsulfonate, its preparation process and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102260250A true CN102260250A (en) | 2011-11-30 |
| CN102260250B CN102260250B (en) | 2013-09-25 |
Family
ID=45007114
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110185120XA Expired - Fee Related CN102260249B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate type II crystal as well as preparation method and application thereof |
| CN 201110185098 Expired - Fee Related CN102321078B (en) | 2005-11-11 | 2006-11-10 | Doxazosin mesylate III form crystal, and preparation method and usage thereof |
| CN 201110185158 Expired - Fee Related CN102260250B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof |
| CN 201110185177 Expired - Fee Related CN102321080B (en) | 2005-11-11 | 2006-11-10 | Doxazosin mesylate V form crystal, and preparation method and usage thereof |
| CN 201110185136 Expired - Fee Related CN102321079B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate crystal VI as well as preparation method and application thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110185120XA Expired - Fee Related CN102260249B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate type II crystal as well as preparation method and application thereof |
| CN 201110185098 Expired - Fee Related CN102321078B (en) | 2005-11-11 | 2006-11-10 | Doxazosin mesylate III form crystal, and preparation method and usage thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110185177 Expired - Fee Related CN102321080B (en) | 2005-11-11 | 2006-11-10 | Doxazosin mesylate V form crystal, and preparation method and usage thereof |
| CN 201110185136 Expired - Fee Related CN102321079B (en) | 2005-11-11 | 2006-11-10 | (-) doxazosin mesylate crystal VI as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN102260249B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102816154B (en) * | 2012-09-10 | 2015-08-19 | 刘庆彬 | A kind of non-crystalline state one hydration (-)-doxazosin mesylate, preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009783A1 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
| WO1994009785A2 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
| WO1994009782A1 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (-) doxazosin for the treatment of hypertension |
-
2006
- 2006-11-10 CN CN201110185120XA patent/CN102260249B/en not_active Expired - Fee Related
- 2006-11-10 CN CN 201110185098 patent/CN102321078B/en not_active Expired - Fee Related
- 2006-11-10 CN CN 201110185158 patent/CN102260250B/en not_active Expired - Fee Related
- 2006-11-10 CN CN 201110185177 patent/CN102321080B/en not_active Expired - Fee Related
- 2006-11-10 CN CN 201110185136 patent/CN102321079B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009783A1 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
| WO1994009785A2 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
| WO1994009782A1 (en) * | 1992-11-04 | 1994-05-11 | Sepracor, Inc. | Methods and compositions of (-) doxazosin for the treatment of hypertension |
Non-Patent Citations (1)
| Title |
|---|
| PAUL K. OWENS等: "Chiral Recognition in Liquid Chromatography Utilising Chargeable Cyclodextrins for Resolution of Doxazosin Enantiomers", 《CHIRALITY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102321079B (en) | 2013-08-28 |
| CN102321078B (en) | 2013-08-28 |
| CN102260249A (en) | 2011-11-30 |
| CN102260250B (en) | 2013-09-25 |
| CN102321080A (en) | 2012-01-18 |
| CN102260249B (en) | 2013-11-13 |
| CN102321079A (en) | 2012-01-18 |
| CN102321080B (en) | 2013-09-25 |
| CN102321078A (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE72967B1 (en) | R(+)-Terazosin | |
| US5998467A (en) | Medicine for oculopathy | |
| CN109734701A (en) | ROCK inhibitor-dichloroacetic acid double salt and its preparation method and application | |
| WO1993000094A2 (en) | Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine | |
| CN100999519B (en) | (-) poly thaazoleazine methylsulfonate, its preparation process and use | |
| CN108250058A (en) | PPAR agonists and its purposes in treatment senile dementia and other diseases | |
| WO2011160597A1 (en) | Furocoumarin compounds with antihypertensive activity and preparation methods thereof | |
| CN114716346B (en) | 4-nitroaniline derivative and application thereof | |
| CN102260250B (en) | (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof | |
| JP2002514578A (en) | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis | |
| WO2020177291A1 (en) | Fasudil compound salt, preparation method therefor and use thereof | |
| CN1746168B (en) | Optically active doxazosin | |
| CN101108847B (en) | (+) doxazosin mesylate, method of manufacturing the same and use thereof | |
| JPH04178356A (en) | Optically active benzylalcohol derivative and its use | |
| CN101397296A (en) | Levalfuzosin, preparation method and use thereof | |
| WO2005003146A1 (en) | The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same | |
| WO2020249120A9 (en) | Use of aminothiol compounds as cerebral nerve or heart protective agent | |
| CN1769285B (en) | Doxazosin salt with optical activity | |
| CN1923205B (en) | Application of (-)doxazosin in preparing medicine for treating lower urinary tract symptom and bladder excessive activities diseases | |
| WO1992022545A1 (en) | New coumarin derivatives | |
| EP0431741A2 (en) | Substituted pyrimidineamino compounds | |
| CN110041244B (en) | Donepezil and valsartan co-amorphous compound, preparation method, composition and application thereof | |
| US6329393B1 (en) | Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative | |
| CN101628899A (en) | 1-(2-methoxypheny1)-4-[3-(naphthalene-1-oxy)-2-hydroxypropyl] piperazine optical isomer and salt thereof, preparation method and application | |
| CN112010914B (en) | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130925 Termination date: 20181110 |